Ones To Watch News
Refine search
Pharmaceutical
Health Canada has authorized Livmarli (maralixibat) oral solution and tablet formulation for the treatment of cholestatic pruritus in patients aged 12 months or older with progressive familial intrahepatic cholestasis (PFIC), Mirum Pharmaceuticals announced on Friday. 7 February 2026
article
US biotech Eikon Therapeutics has raised about $381 million in the largest biotech IPO of the year so far, but the market’s first reaction was cautious. Shares fell nearly 17% on their first day of trading, closing at $15. 6 February 2026
Biotechnology
Swiss biotech firm Idorsia today announced the design of its US Food and Drug Administration (FDA)-agreed Phase III registration program for lucerastat in Fabry disease. 6 February 2026
Biotechnology
Following on from a host of successful or planned initial public offerings (IPOs) in biotech so far this year, another firm has lined up a listing. 6 February 2026
Biotechnology
Privately-held San Diego biotech ADARx Pharmaceuticals announced the appointment of Dr Donald Fong as chief medical officer (CMO) to lead the advancement of its clinical-stage pipeline. 6 February 2026
Pharmaceutical
Swedish life sciences investor Karolinska Development says its portfolio company SVF Vaccines has agreed a reverse acquisition with Novakand Pharma, a move that would put SVF into a publicly listed vehicle. 6 February 2026
Biotechnology
California-based Braveheart Bio, a biotech developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and related cardiovascular conditions, has announced that Marc Evanchik has been promoted to chief scientific officer (CSO). 5 February 2026
Biotechnology
USA-based clinical-stage dermatology start-up Veradermics has announced the pricing of its upsized initial public offering of 15,077,647 shares of its common stock at an initial public offering price of $17.00 per share. All of the shares are being offered by Veradermics. 5 February 2026
Biotechnology
Pennsylvania, USA-based Third Arc Bio, a biotech company developing novel multifunctional antibodies for a range of oncology and immunology & inflammation (I&I) indications, has announced the closing of a $52 million series A extension. 4 February 2026
Biotechnology
UK biotech Levicept, which is focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis (OA), today announced the appointment of James Sandy as chief development officer (CDO). 4 February 2026
Biotechnology
Cambridge, UK-based biotech Bicycle Therapeutics, which is pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced leadership transitions for its next phase of innovation. 3 February 2026
Biotechnology
Privately-held RNAi therapeutics specialist SanegeneBio has announced a global licensing agreement with the Roche subsidiary Genentech. 3 February 2026
Biotechnology
Norwegian cell therapy developer Zelluna has promoted Emilie Gauthy to chief technology officer, effective immediately. Ms Gauthy joined the company in 2022 and has led manufacturing and chemistry, manufacturing and controls work as Zelluna prepares to enter the clinic. 3 February 2026
Biotechnology
US biotech Wave Life Sciences has regained full rights to WVE-006 from British pharma GSK, bringing the RNA-editing therapy for alpha-1 antitrypsin deficiency back in-house as it prepares for higher-dose clinical data and steps up regulatory engagement. 3 February 2026
Biotechnology
US clinical-stage biotech Sagimet Biosciences’ shares rose 10% to $6.23 after it announced that China-based partner Ascletis Pharma reported positive top-line results in the open-label Phase III trial evaluating the long-term safety of ASC-40 (denifanstat) tablets in patients with moderate to severe acne. 3 February 2026
Pharmaceutical
Australian radiopharmaceutical company AdvanCell has entered into a collaboration and exclusive licensing deal with Canadian biotech 48Hour Discovery to develop a novel peptide-based Lead-212 (212Pb) radiotherapeutic. 2 February 2026
Biotechnology
To date, 2025 has been the most active year for LifeArc Ventures. 2 February 2026
Biotechnology
French immuno-oncology company Kahimmune Therapeutics has announced the signing of an exclusive licensing agreement with cancer research hospital Gustave Roussy and technology transfer specialist SATT Paris-Saclay. 2 February 2026
Biotechnology
Australian oncology-focused biotech Kazia Therapeutics has reported pre-clinical and translational data supporting NDL2, a protein degrader designed to eliminate nuclear PD-L1, an intracellular driver of immunotherapy resistance and metastasis not addressed by approved checkpoint antibodies. 2 February 2026
Biotechnology
US genomics specialist Illumina has completed its acquisition of proteomics company SomaLogic, adding large-scale protein analysis to its multiomics portfolio and strengthening its push beyond sequencing into faster drug discovery and biomedical research. 2 February 2026
Biotechnology
Cambridge, USA-based CAMP4 Therapeutics has entered into a strategic research, collaboration and license agreement with UK pharma major GSK to identify and develop antisense oligonucleotide (ASO) drug candidates for multiple gene targets relevant to neurodegenerative and kidney disease indications. 18 December 2025
Pharmaceutical
California, USA-based Vistagen yesterday announced that the PALISADE-3 Phase III study of intranasal fasedienol for the acute treatment of social anxiety disorder did not demonstrate a statistically significant improvement on the primary endpoint of change on the Subjective Units of Distress Scale (SUDS). 18 December 2025
Pharmaceutical
US biotech Cytokinetics has secured the first global approval for its cardiac myosin inhibitor aficamten, after China’s National Medical Products Administration cleared the drug for adults with NYHA class II-III obstructive hypertrophic cardiomyopathy. The treatment will be marketed locally as Myqorzo by Sanofi. 18 December 2025
Biotechnology
Sino-US biotech Harbour BioMed, which is focused on the discovery and development of novel antibody therapeutics in immunology and oncology, has announced a multi-year, global strategic collaboration and license agreement with Bristol Myers Squibb to discover and develop next-generation multi-specific antibodies. 18 December 2025
Biotechnology
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted a new indication for Dutch immunology company argenx Vyvgart (efgartigimod alfa) under the reliance review process sending the firm’s shares up 2% to 742.20 euros. 17 December 2025
Biotechnology
German biotech T-CURX today announced the first closing of a $20 million (17.7 million) Series A financing with a syndicate of European and Asian investors for accelerating clinical development of T-CURX non-viral clinical CAR-T therapies in AML and solid tumor indications, as well as advancing T-CURX proprietary non-viral technologies for in vivo CAR-T generation. 17 December 2025
Pharmaceutical
US clinical-stage oncology company NanOlogy has appointed David Arthur as chief executive, as it accelerates development of its large surface area microparticle drug platform and prepares a regulatory filing for a rare pediatric brain cancer program. 17 December 2025
Pharmaceutical
Canadian biotech Oncolytics Biotech has reported encouraging clinical and translational data for its oncolytic virus therapy pelareorep in second-line metastatic colorectal cancer with KRAS mutations and microsatellite-stable disease, one of the hardest segments to treat. 17 December 2025
Biotechnology
US biotech ImmunityBio announced that treatment with Anktiva (nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) demonstrates efficacy at 12 and 36 months, including disease-free survival (DFS). 17 December 2025
Biotechnology
California, USA-based clinical-stage biopharmaceutical company Aeovian Pharmaceuticals revealed it has closed an oversubscribed $55 million Series B financing that will fund completion of a Phase II proof-of-concept study for its lead development candidate, AV078, in tuberous sclerosis complex (TSC)-related refractory epilepsy. 17 December 2025
Pharmaceutical
French biopharma DBV Technologies has rewarded the faith of long-term investors with compelling pivotal Phase III results on its Viaskin Peanut allergy patch from the VITESSE trial. 17 December 2025
Biotechnology
UK-based immunology specialist Allergy Therapeutics has announced that the Paul Ehrlich Institut (PEI) has granted a marketing authorization in Germany for the group's subcutaneous grass pollen allergen immunotherapy, Grass MATA MPL. 16 December 2025
Biotechnology
USA-based XOMA Royalty Corporation is to acquire Generation Bio for around $4.29 per share. 16 December 2025
Biotechnology
US biotech Immunome has announced positive top-line results from the global pivotal Phase III RINGSIDE trial of varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), in patients with progressing desmoid tumors. 16 December 2025
Pharmaceutical
UK-based Bicycle Therapeutics, a pharma company developing a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, has entered into a 15-year contract including an option to renew with the UK Nuclear Decommissioning Authority (NDA) for access to up to 400 tonnes of reprocessed uranium (RepU). 16 December 2025
Biotechnology
Link Cell Therapies, an oncology cell therapy company, has announced its official launch from stealth with a $60 million Series A financing that was led by Johnson & Johnson. 15 December 2025
Biotechnology
California-based Tenaya Therapeutics, a biotech seeking to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, has announced the pricing of a $60 million public offering. 15 December 2025
Biotechnology
US biopharma Arcus Biosciences has announced the discontinuation of the Phase III STAR-221 study, being conducted in partnership with Gilead Sciences (Nasdaq: GILD), due to futility. 15 December 2025
Biotechnology
Swedish Orphan Biovitrum, also known as Sobi, has entered into a definitive agreement to acquire San Diego, USA-based biotech Arthrosi Therapeutics, a private late-stage biotechnology company focused on developing a next-generation treatment for gout. 15 December 2025
Pharmaceutical
British pharma major AstraZeneca has joined a near-$100 million series A and A+ financing round for Syneron Bio, a biotechnology startup focused on macrocyclic peptide therapies for oncology and chronic diseases. 12 December 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze